Background/Aims: Rats with subtotal nephrectomy (5/6NPX) rapidly develop systemic hypertension and proteinuria. The aim of our study was to evaluate the changes in oxidative stress parameters after 2 and 4 weeks of treatment with renin-angiotensin system (RAS)-blocking agent losartan and beta-blocking agent atenolol in experimental chronic renal failure (CRF). Methods: After 5/6NPX, rats were immediately treated with losartan or atenolol. The lipid peroxidation (LPO) products malondialdehyde and 4-hydroxyalkenals and oxidized and reduced glutathione values were measured in the renal cortex tissue and in blood; isoprostanes in urine. Results: There were no differences in the blood pressure values, serum creatinine levels or in daily proteinuria using both antihypertensive treatments. Losartan treatment lowered significantly LPO in kidney tissue after 2 and 4 weeks of treatment compared with untreated and atenolol-treated animals and induced the decrease of excretion of isoprostanes in urine at the end of the study. There was no ameliorating impact of losartan or atenolol observed in the blood status of oxidative stress in this period of time. Conclusion: In the early period of experimental CRF, losartan treatment but not atenolol treatment induces significant decline in LPO grade in the kidney tissue of nephrectomized rats. RAS blockade in the kidney influences local tissue LPO in a much greater extent than in blood.

1.
Nath KA, Croatt AJ, Hostetter TH: Oxygen consumption and oxidant stress in surviving nephrons. Am J Physiol 1990;258:F1354–F1362.
2.
Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M: Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 2002;61:586–590.
[PubMed]
3.
Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524–1538.
[PubMed]
4.
Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J: Role of the renin-angiotensin system in vascular diseases: Expanding the field. Hypertension 2001;38:1382–1387.
[PubMed]
5.
Romero JC, Reckelhoff JF: State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999;34:943–949.
[PubMed]
6.
Nemeth I, Orvos H, Boda D: Blood glutathione redox status in gestational hypertension. Free Radic Biol Med 2001;30:715–721.
[PubMed]
7.
Turi S, Friedman A, Bereczki C, Papp F, Kovacs J, Karg E, Nemeth I: Oxidative stress in juvenile essential hypertension. J Hypertens 2003;21:145–152.
8.
Wang D, Chen Y, Chabrashvili T, Aslam S, Borrego Conde LJ, Umans JG, Wilcox CS: Role of oxidative stress in endothelial dysfunction and enhanced responses to angiotensin II of afferent arterioles from rabbits infused with angiotensin II. J Am Soc Nephrol 2003;14:2783–2789.
9.
Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998;9:224–230.
[PubMed]
10.
Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine, ed 3. Oxford, Oxford University Press, 1999, pp 140–163, 393–430.
11.
Griffith OW: Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980;106:207–212.
[PubMed]
12.
Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981;241:F85–F93.
13.
Ritz E, Haxsen V: Angiotensin II and oxidative stress: an unholy alliance. J Am Soc Nephrol 2003;14:2985–2987.
14.
Agarwal R: Proinflammatory effects of oxidative stress in chronic kidney disease: Role of additional angiotensin II blockade. Am J Physiol Renal Physiol 2003;284:F863–F869.
15.
Donmez G, Derici U, Erbas D, Arinsoy T, Onk A, Sindel S, Hasanoglu E: The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension. Jpn J Physiol 2002;52:435–440.
16.
Welch WJ, Wilcox CS: AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int 2001;59:1257–1263.
[PubMed]
17.
Welch WJ, Baumgartl H, Lubbers D, Wilcox CS: Renal oxygenation defects in the spontaneously hypertensive rat: Role of AT1 receptors. Kidney Int 2003;63:202–208.
[PubMed]
You do not currently have access to this content.